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Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been
approved to treat complicated infections in the clinic because of its expanded-spectrum
antibiotic potential. Recently, an increasing number of studies have emphasized the
anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several
activating signaling pathways and abnormal mitochondrial function in cancer cells. The
aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG
activity against different cancer types, including acute myeloid leukemia (AML), glioma,
non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side
effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to
be discussed that will evaluate the security and validate the underlying the tumor-killing
properties of TIG.
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INTRODUCTION
Advances in genomic knowledge are providing attractive insights into the biology of human
cancers, but the development of novel pharmacologic agents has not proceeded as quickly
(Waldron, 2016). Identification of novel molecular events, such as gene expression signatures and
mutation assessment, has yielded tremendous insights into cancer pathogenesis. However, many
molecular expression patterns, highlighted by studies over the past decade, such as loss- or gain-of-
function mutations in the WIP1 (wild-type p53-induced phosphatase 1) gene, have not produced
straightforward therapeutic targets (Ruark et al., 2013). An alternative strategy for therapeutic
identification is to screen on- and off-patent drugs with potential anti-cancer properties that are
not directly related to the gene mutations.
Tigecycline (TIG), an FDA (U.S. Food and Drug Administration) approved glycylcycline
antimicrobial agent, is widely used to treat complicated intra-abdominal infections (IAIs)
and skin-structure infections (SSIs) (Bradford et al., 2005). Studies have indicated that TIG
exhibits broad spectrum anti-bacterial ability against Gram-positive and Gram-negative bacteria,
including Staphylococcus aureus (Sader et al., 2016), Acinetobacter baumannii (Rao et al., 2016),
Enterobacteriaceae (Thaden et al., 2016), among others. As an expanded-spectrum antibiotic,
TIG is clinically available for bacterial eradication with a good safety and tolerability profile,
particularly for cancer patients (Lauf et al., 2014). Because of intensive myelosuppressive
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chemotherapy (Razzouk et al., 2006) and surgical site infections,
cancer patients are susceptible to infections (Teillant et al., 2015).
In a multicenter, open-label, randomized and superiority trial,
390 febrile neutropenic participants with cancer were enrolled
and randomly assigned to receive piperacillin/tazobactam with
or without TIG. Compared with the monotherapy group, the
clinical outcome is significantly higher in the combination
group, indicating that TIG could be considered as one of the
first-line empiric antibiotic therapies for cancer patients with
a pathogen infection (Bucaneve et al., 2014). In addition, a
growing body of evidence shows that TIG possesses direct anti-
tumor effects in vivo and in vitro. Skrtic’s group found that TIG
could selectively induce cell death in a panel of leukemia cell
lines without obvious side effects on normal hematopoietic cells.
Meanwhile, combining TIG with daunorubicin or cytarabine,
two standard chemotherapeutics that are used for acute myeloid
leukemia (AML), exhibits an additive or synergistic cytotoxic
effect (Jaras and Ebert, 2011; Schimmer and Skrtic, 2012).
Therefore, in this review, we mainly focus on updating the
findings regarding the anti-tumor activity of TIG and discuss
well-investigated signaling molecules related to the anti-cancer
effects of TIG. In addition, as a promising chemotherapy drug
which may be used clinically in the future, the effectiveness and
adverse effects of TIG will also be discussed.
MITOCHONDRION AS A TARGET OF TIG
Mitochondria, the energy house of cells, are semiautonomous
organelles, as they contain their own genetic material –
mitochondrial DNA (mtDNA). The mtDNA is a double-stranded
circular genome without introns that can be transcribed into
2 ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs)
and encodes 13 of 90 proteins required for electron transport
by the respiratory chain. In addition, mitochondrial protein
synthesis depends on the unique protein translation mechanism,
including particular initiation and elongation factors that differ
from eukaryotic cytosolic factors (Zong et al., 2016). Multiple
studies have illustrated that mitochondria are not only critical for
normal cell function, they also play a role in malignant tumor
progression (Quiros et al., 2015; Bender and Martinou, 2016).
Since they were discovered in approximately the 1890s by
Richard Altmann and Carl Benda, two famous German scientists,
mitochondria have attracted increasing interest of scientists. In
the following decades, the understanding of mitochondrial
function has grown enormously thanks to advances in
biochemical and genetics technologies (Picard et al., 2016). In
physiological conditions, a major function of mitochondria is to
generate the energy-rich molecule adenosine triphosphate (ATP),
promoting cell survival. Moreover, mitochondria are signaling
structures that allow the cell to adapt to the environment by
sensing stress. Many other biologic behaviors support these
mitochondrial functions, including biosynthetic metabolism,
fusion dynamics, oxidative stress responses, and so on (Nicholls
and Budd, 2000). Recent studies have highlighted the importance
of the mitochondrial machinery in human diseases, such as
age-related disorders (Sun et al., 2016) and cancers (Vyas
et al., 2016). Numerous studies on the mitochondrial roles
in cancer have initiated a novel frontier focus, suggesting the
multifaceted functions of mitochondria in tumorigenesis and
progression. In some cancer types, owing to mitochondrial
functional defects, malignant cells undergo aerobic glycolysis
to maintain rapid proliferation and resistance to therapeutic
stress, which is known as the Warburg effect (Flaveny et al.,
2015). Compared with normal cells, cancer cells exhibit markedly
upregulated glucose uptake and aerobic glycolysis, increasing the
yield of biosynthetic intermediates, providing essential anabolic
molecules for cell proliferation and tumor growth (Ribas et al.,
2016). Gius’s study suggested that knockdown of sirtuins, a
cellular energy sensor, could increase glycolytic metabolism,
further promoting mammary tumor growth (Park et al., 2016).
Loss of mitochondrial PTEN-induced kinase 1 (PINK1) could
promote glioblastoma growth by increasing the Warburg effect
in vitro and in vivo (Agnihotri et al., 2016). However, a more
complex picture is emerging in which some cancer patients
depend on the mitochondria respiratory function. Supporting
this concept, Alam et al. (2016a) demonstrated that enhanced
mitochondrial aerobic respiration is necessary for many types
of cancer cells to gain tumorigenic and drug-resistant potential,
such as non-small cell lung cancer (NSCLC) and breast cancer.
Inhibition of mitochondrial respiration by Hedgehog inhibitors,
such as cyclopamine tartrate, could strongly interfere with cell
proliferation and induce apoptosis in NSCLC (Alam et al.,
2016b). In addition, studies have demonstrated that based on the
context, the mitochondrial mass can serve as either a pro-survival
or pro-death modulator in tumor development and progression
(Joshi et al., 2016). These “pleiotropic effects” could be influenced
by genetic, environmental and tissue-derived differences between
tumors.
Targeting mitochondrial functions, such as mitochondrial
biogenesis, is a successful strategy for cancer therapeutics
(Figure 1). Skrtic´ et al. (2011) found that TIG has selective
toxicity on leukemia cells, especially leukemia stem and
progenitor cells in vitro and in vivo, and this cell cytotoxicity
of TIG depends on the intact respiratory chain. However,
TIG-resistant cancer cells show more resistance to hypoxia
FIGURE 1 | The effect of the antibiotic drug TIG on mitochondrial
function in cancer.
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with an upregulated hypoxia-inducible factor 1α (HIF-1α)
level from defective oxidative phosphorylation (Jhas et al.,
2013). Using the haplo-insufficiency profiling screen, a well-
validated, automated and high-throughput chemogenomic assay
platform developed in yeast, mitochondrial protein synthesis
has been identified as the mechanism of TIG-induced lethality.
Knockout of mitochondrial elongation factor Tu (mEF-Tu), a
key modulator involved in mitochondrial protein translation,
could significantly reproduce the anti-leukemia potential of TIG
(Skrtic´ et al., 2011). The same group also developed a new
formulation that could enhance the stability of TIG in saline
solution as well as preserve the agent’s anti-leukemic activity.
The elements added to this formulation are mainly ascorbic acid
and pyruvate (Jitkova et al., 2014). Apart from its anti-leukemic
effect, recent studies have demonstrated that TIG could target
multiple cancers by impairing mitochondrial functions (Lamb
et al., 2015). For example, Jia et al. (2016) found that TIG
could significantly reduce growth and induce apoptosis in various
NSCLC cell lines through inhibition of mitochondrial function.
Inhibiting the mitochondrial gene expression and translation
pathway by TIG could induce MYC oncogene-dependent tumor
cell death, including the osteosarcomas (Oran et al., 2016) and
lymphomas (D’Andrea et al., 2016). As the mitochondrial energy
metabolism provides distinct pro-survival benefits to diffuse large
B-cell lymphomas (DLBCLs), pharmacological perturbation of
the mitochondrial translation pathway with TIG is proved to be
selectively toxic to DLBCL cell lines (Norberg et al., 2016). In
addition, another group has identified that TIG could serve as
a potential new therapeutic drug for treatment of retinoblastoma
(RB1) -deficient breast cancer (Jones et al., 2016). Therefore, an
important consideration in anti-cancer fields will be addressing
mitochondrial signaling modulation with chemical compounds.
Akt SIGNALING AS A TARGET OF TIG
Akt, also known as protein kinase B (PKB), belongs to
an evolutionarily conserved serine-protein kinase family and
participates in cell homeostasis maintenance by regulating
numerous downstream effectors. The Akt family mainly contains
three members, Akt1 (PKBα), Akt2 (PKBβ), and Akt3 (PKBγ),
which share more than 80% structure homology. All of these
isoforms contain three similar domains with an N-terminal
pleckstrin homology motif, central kinase catalytic motif, and
C-terminal hydrophobic motif tail (Sussman et al., 2011). Since
its discovery, numerous efforts have been made to clarify
the mechanism of Akt activation. Studies have indicated that
the Akt signaling pathway could be activated by receptor
tyrosine kinases (RTKs), including insulin-like growth factor 1
receptor (IGF-1R), epidermal growth factor receptor (EGFR)
and others (Manning and Cantley, 2007). Upon stimulation
by RTKs, phosphatidylinositol 3-kinase (PI3K) is recruited
to the plasma membrane, which subsequently catalyzes the
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2)
to generate phosphatidylinositol 3,4,5-triphosphate (PIP3). Then,
the accumulation of PIP3 activates Akt by phosphorylation
modification at two regulatory sites, Thr308 and Ser473 (Cantley,
2002). In addition to RTKs, Akt activity can be modulated
by lipid and protein phosphatases, such as phosphatase and
tensin homolog (PTEN) and protein phosphatase 2A (PP2A).
PTEN is a negative modulator of the Akt signaling pathway,
and inhibition of PTEN by a small-molecule inhibitor could
significantly activate Akt (Shojaee et al., 2016). Similarly, PP2A
can down-regulate Akt activation by directly promoting Thr308
dephosphorylation (Liu et al., 2016). Additionally, once Akt is
locked in the active confirmation, it can regulate more than
100 down-stream factors that are involved in diverse cellular
functions, including cell proliferation, apoptosis, metabolism,
and so on. These direct substrates of Akt all share a consensus
phosphorylated minimal motif (R-X-R-X-X-pS/pT) (Carmona
et al., 2016). For example, AKT phosphorylates glycogen synthase
kinase-3β (GSK3β) at Ser9 and thus inactivates it, which
promotes Erb-B2 receptor tyrosine kinase 2 (ErbB2)-mediated
cardiomyocyte proliferation (D’Uva et al., 2015). Akt-dependent
phosphorylation of mTOR complex 1 (mTORC1) plays an
important role in the self-renewal capacity of hematopoietic or
leukemia stem cells (Lechman et al., 2016).
To date, molecular screening of human disease models,
particularly for cancer, has identified a series of alterations that
affect the Akt signaling pathways. It is of particular interest
to explore the possible molecular mechanism underlying Akt
activation, which is a potential contributor to cancer cell
development (Fortin and Mak, 2016). The most common type
of mechanism is from loss- or gain-of-function. Due to frequent
mutation, loss-of-function of PTEN is a canonical event in
cancer cells. PTEN loss results in continuous activation of Akt
signaling, which is correlated with the shorter overall survival of
BRAFV600E mutated melanoma patients (Bucheit et al., 2014).
However, using whole-genome sequencing, Costa et al. (2015)
identified a novel point mutation (A126G) in the PTEN protein.
They found that unlike canonical loss-of-function mutants,
A126G mutation could produce an enzymatic gain-of-function
in PTEN, activating the Akt signaling pathway and prompting
cell proliferation in prostate cancer (Costa et al., 2015). These
findings suggest the crucial role of the PTEN mutation in the Akt
pathway in cancer. The second mechanism is a compensatory
effect. Inhibition of Akt has a negative feedback effect on RTK
activation, which then enhances Akt activation. Akt inhibitors,
AKTi-1/2 and MK-2206, could re-activate RTK signaling in a
FOXO-dependent manner, attenuating the anti-tumor effects of
these inhibitors (Chandarlapaty et al., 2011). As a result, it is
critically important to clarify the detailed mechanism of the
Akt signaling pathway, which will help develop a more efficient
treatment strategy, including pharmacologic therapies.
Antibiotic TIG has an attractive anti-proliferation effect on
neuroblastoma cells by dephosphorylating Akt and its down-
stream targets in vitro and in vivo (Figure 2). The Akt
activator IGF-1 significantly rescues the inhibition effects of
TIG (Zhong et al., 2016). Further study demonstrated that after
treating glioma U87 and U128 cells with TIG, the miRNA-
199b-5p level obviously increased and the level of HES family
BHLH transcription factor 1 (HES1), a target of miRNA-
199b-5p, obviously decreased. Moreover, TIG decreased Akt
phosphorylation at Ser473 and increased its target p21 level
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FIGURE 2 | Overview of the antibiotic drug TIG on the aberrant Akt signaling for cancer research and therapy.
via the miRNA-199b-5p-HES1 axis (Yang et al., 2016). Another
study showed that TIG could induce cell G1/S phase arrest and
suppress migration/invasion by down-regulating the level of p21
in melanoma A375 and MV3 cell lines (Hu et al., 2016). These
contrary roles of p21 might be due to its subcellular localization.
In its traditional function, nuclear p21 acts as a dominant
cyclin-dependent kinase (CDK) inhibitor that facilitates tumor
suppression. While in the cytoplasm, p21 also exhibits oncogenic
properties by interacting with a large set of molecules involved
in cell proliferation, apoptosis, metastasis, and so on (Abbas and
Dutta, 2009). In addition, it confirmed that the mammalian target
of rapamycin (mTOR) also serves as a central factor underlying
the Akt signaling pathway. Cui’s group found that TIG could
induce autophagic cell death in gastric cancer cells, GAM-016 and
MKN-45, by abrogating mTOR phosphorylation at the Ser2448
position (Tang et al., 2014). Taken together, TIG could act as a
powerful candidate for intervening in the Akt signaling pathway
for cancer therapy.
Wnt/β-CATENIN SIGNALING AS A
TARGET OF TIG
Wnt, a secreted and lipid-modified glycoprotein, can activate a
variety of cellular surface receptor-mediated signal transduction
pathways that are involved in embryonic development and
normal tissue homeostasis. In the canonical Wnt pathway,
Wnt signaling inhibits β-catenin degradation, which can result
in changes in various genes at the transcription level, such
as the transcription factors HOXA5 (Ordonez-Moran et al.,
2015) and ZEB1 (Wang et al., 2014). Several studies have
revealed that activation of the Wnt signaling pathway is a
hallmark of many human cancers (Clevers, 2006). Therefore,
identification of the components of the Wnt/β-catenin pathway
can provide promising targets for developing therapeutic agents.
In a recent report, using the TOPflash reporter activity assay,
Li et al. (2015) found that TIG decreased the Wnt/β-catenin-
mediated transcription in cervical squamous cell carcinoma and
that overexpression of exogenous β-catenin could abolish the
inhibitory effects of TIG on cancer cells.
SAFETY AND EFFICACY
TIG is a novel injectable antimicrobial with a broader spectrum
of in vivo activity against a large number of Gram-positive
as well as Gram-negative pathogenic bacteria. Some studies
so far have evaluated its use in different hospital settings
and microorganisms (Table 1). A recent retrospective study in
patients with nosocomial IAIs showed that clinical response
rate with TIG at standard dosage (initial dose of 100 mg,
followed by 50 mg every 12 h) is approximately 78.3%., and
none of the patients discontinued TIG treatment due to the side
effects (Maseda et al., 2013). Furthermore, higher dosage TIG
regimens (initial dose of 200 mg, followed by 100 mg every 12 h)
could be potentially used to treat the severe hospital-acquired
infections (Ramirez et al., 2013). In addition, three pediatric cases
all demonstrated that TIG could effectively kill the multidrug-
resistant pathogens in children with AML, with favorable safety
and toleration (Dinleyici et al., 2010; Ozdemir et al., 2012; Tugcu
et al., 2015). Nevertheless, for patients who have been long-
term exposed to broad-spectrum antibiotic TIG, conditional
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TABLE 1 | The efficacy and side-effects of TIG in clinical cases.
Patients Diseases Response rate Side-effects Reference
215 Chryseobacterium indologenes infections 51.9% for blood isolates; 39.1% for sputum
isolates
N/A Chen et al., 2013
110 Cancer 64% Gastrointestinal disorders Chemaly et al., 2009
199 Intra-abdominal infections 86.5% for ME populations, 81.7% for mITT
populations
Gastrointestinal disorders Chen et al., 2010
24 Cancer 48% 4% increased liver enzyme serum
concentrations
Secondo et al., 2010
2 BMT N/A Marrow toxicity Maximova et al., 2013
114 Hospital-acquired pneumonia 85% for TIG 100 mg;
69.6% for TIG 75 mg
Gastrointestinal disorders Ramirez et al., 2013
23 Intra-abdominal infections 78.3% None Maseda et al., 2013
170 Secondary bacteremia 81.3% 2.2% mortality Gardiner et al., 2010
35 Hematological malignancies 43% Gastrointestinal disorders, Liver and
renal toxicity
Schwab et al., 2014
3788 Inflammation N/A <1% pancreatitis McGovern et al., 2014
1 AML N/A None Dinleyici et al., 2010
N/A, not available; ME, microbiologically evaluable patients; mITT, modified intent-to-treat patients; BMT, bone marrow transplantation; AML, acute lymphoblastic leukemia.
pathogens such as Chryseobacterium indologenes could cause
various types of refractory infectious events (Chen et al., 2013).
Furthermore, according to the FDA drug safety communication,
researchers pointed out that compared to comparator-treated
patients, the TIG-treated patients showed an increased risk of
mortality ranging from 3 to 4%, with the clinical cure rates
increased from 78.5 to 81.3% (Gardiner et al., 2010; Averbuch
et al., 2013). Moreover, data of 35 febrile neutropenic patients
with hematological malignancies indicated that 2.9% of patients
treated with TIG have to be terminated owing the intolerable
nausea and headache (Schwab et al., 2014). Recently, Maximova
et al. (2013) reported the myelotoxicity of TIG in two boys
who underwent the bone marrow transplantation. Through
analyzing the clinical characteristics, they found that TIG could
significantly reduce the cellular viability of bone marrow cells in
a dose-dependent manner (Maximova et al., 2013). Another case
of the toxicity of TIG has been reported by Mcgovern et al. (2014)
via analysing the subject data from phases III and IV comparative
studies, which demonstrated adverse events of pancreatitis are
also uncommon in patients treated with TIG, with an occurrence
of<1% (McGovern et al., 2014). These occasional serious adverse
reactions of TIG should arouse urgent attention of the researchers
and clinicians, which requires further evaluation.
Apart from the infrequent complications mentioned above,
the most common adverse effects (incidence >5%) associated
with the use of TIG have been confined to gastrointestinal
symptoms, including nausea, vomiting, and diarrhea in the
infected population, particularly in patients with cancers
(Kosmidis and Chandrasekar, 2012). Phase III clinical trials
conducted by Cooper’s group suggested that upon treated
by TIG, the incidence of nausea, vomiting and diarrhea are
21.6, 12.4, and 5.2%, respectively (Chen et al., 2010). Another
retrospective review of 110 cancer patients reported that
about 64% participants have an overall clinical response to
TIG. Interestingly, the incidence of gastrointestinal symptoms
dropped below 5% (5% for mile nausea, 2% for vomiting, and
4% for diarrhea, respectively), which are mainly due to the
antiemetics and ventilator support at the start of TIG therapy
(Chemaly et al., 2009). These findings suggest that administration
of supportive medications prior to TIG could significantly
reduce the incidence of gastrointestinal side-effects. Finally, other
mild side-effects associated with TIG administration were also
recorded, such as increased serum concentrations of liver enzyme
(Secondo et al., 2010) and liver and renal toxicity (Schwab
et al., 2014). Collectively, these studies illustrate the unique
clinical presentation in the process of treatment with TIG for
infections in patients, particularly in cancer patients. Evidently,
more investigations on clinical application of TIG are required
to reveal the details regarding the safety and efficacy of TIG.
Without any doubt, these observations will shed more light on
how to treat infection or cancer with TIG properly without
inducing apparent and serious adverse effects.
PERSPECTIVE IN CLINICAL TRIALS
Up to now, several therapeutic molecules that inhibit cancer-
associated signaling pathways, such as dichloroacetate (DCA),
an inhibitor of the mitochondrial pyruvate dehydrogenase
kinase, have been used in clinical trials1. As Akt signaling
and mitochondrial biology both participate in the physiological
behaviors, the clinical use of their corresponding inhibitors would
cause side effects in a certain extent. Chu et al. (2015) conducted
an open-labeled, single-arm, dose-escalation study of DCA in 24
patients with advanced solid malignancies and found that the
response to DCA with grade I-II toxicities can be evaluated in
most patients. Another dose/schedule-finding study by Tolcher
et al. (2015) indicated that patients with advanced treatment-
refractory solid tumors show partial responses to MK-2206
treatment with obvious dose-limiting toxicity. As a result, future
1https://clinicaltrials.gov/
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clinical trials to verify the efficacy of new anti-cancer compounds
in multiple human cancers are now clearly warranted. In a clinical
trial conducted by Bucaneve et al. (2014), the combination of
piperacillin/tazobactam and TIG was more effective for treating
hematologic cancer patients (Bucaneve et al., 2014). Moreover,
TIG is well tolerated and relatively safe, apart from mild
gastrointestinal adverse events (Garrison et al., 2005). Recently,
based on the pre-clinical data mentioned above, TIG has recently
completed a Phase I clinical trial for the treatment of AML with a
favorable safety profile at doses 300 mg/day (clinicaltrials. Gov
ID: NCT01332786) (Reed et al., 2016). Although only a few
issues about the direct tumor-killing effect of TIG have been
preliminarily evaluated in clinical trials so far, studies on the great
biological and clinical efficacy of TIG will light up a promising
way in cancer treatment.
CONCLUSION
In recent decades, molecular screening of cancer tissues and
cells by high-throughput bioinformatics platforms is starting to
guide the target choice for therapeutic interference. Investigation
of the genetic and biological diversity between normal and
cancer cells would help to develop more effective tumor-killing
agents without obvious side effects. For instance, with its
selectively potential for malignant cells, TIG could serve as a lead
candidate for novel chemotherapy- cytotoxic drug development.
In mechanism analysis, the combination of a small compound
screen, yeast chemogenomic platform and further in vitro and
in vivo experiments is conducive to identifying dysregulation
signaling as the target for candidate compounds, such as TIG.
Furthermore, given the issues with clinical application, future
studies should focus on the combined effects between TIG and
standard chemotherapy drugs to effectively treat cancer patients.
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